Ashland (ASH) Q3 2024 earnings summary

Executive summary

• Q3 FY24 sales were $544 million, nearly flat year-over-year, with strong Personal Care growth and improved Specialty Additives volumes offset by Life Sciences declines and increased price pressure.

• Adjusted EBITDA rose 5% to $139 million, with margin recovery driven by volume gains, favorable mix, and disciplined price management.

• Net income for Q3 2024 was $6 million, down from $50 million prior year, impacted by a $99 million impairment charge related to the planned sale of the Nutraceuticals business and restructuring costs.

• Portfolio optimization initiatives, including divestiture of the nutraceuticals business and consolidation of select product lines, reduced sales by $15 million in Q3 and are expected to further impact Q4 and FY2025.

• Free cash flow was strong at $112 million, supporting $130 million in share repurchases and a dividend increase.

Financial highlights

• Gross profit margin increased 290 basis points to 36.2%, among the highest in five years.

• Adjusted EBITDA margin improved to 25.6% from 24.4% year-over-year.

• Adjusted EPS (excluding acquisition/amortization) was $1.49, up 21% year-over-year.

• Cash on hand at quarter-end was $399 million, with total liquidity of ~$1 billion and net debt of $926 million (2.3x leverage).

• Ongoing free cash flow conversion was 81% for the quarter.

Outlook and guidance

• Q4 FY24 sales expected at $530–$540 million and adjusted EBITDA at $130–$140 million.

• Full-year FY24 sales projected at ~$2.1 billion and adjusted EBITDA at $465–$475 million.

• Portfolio optimization expected to reduce FY2025 revenue by $160–$170 million, mainly from Life Sciences.

• Free cash flow conversion for FY2024 expected at 50–55%.

• End market demand growth estimated flat to low single digits; mid-single-digit sales volume growth expected in Q4, offset by low-single-digit pricing declines.